ArticleScientific reports2025
Comparative survival outcomes of lobectomy versus total thyroidectomy in T1 and T2 papillary thyroid cancer with more than five positive lymph nodes.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The surgical approach for papillary thyroid cancer (PTC) by either lobectomy or total thyroidectomy (TT) has long been a topic of debate, especially for patients with intermediate-risk PTC, such as T1 and T2 stage patients with more than five positive lymph node metastases (LNM). This study analyzed a population-based retrospective cohort of T1 and T2 PTC patients with more than five positive LNM from the SEER database (2004-2017), comparing clinicopathologic features and survival outcomes between those undergoing lobectomy and TT. Cox proportional hazards regression analysis to explore prognostic factors of survival. Propensity score matching (PSM) was used to balance covariates. The study included 5,610 patients, with 5,322 (94.87%) receiving TT and 288 (5.13%) undergoing lobectomy. Patients in the TT group had higher rates of N1b stage diagnoses, multifocal lesions, and more lymph nodes examined and more lymph nodes positive. Survival analysis showed no difference in overall survival (OS) between the groups (p = 0.177), but a significant difference in cancer-specific survival (CSS) (p < 0.001). After 1:1 PSM, there were no significant difference in OS (p = 0.089) and CSS (p = 0.350). Additionally, stratified analysis showed no significant difference in OS and CSS between patients treated with TT plus radioactive iodine (RAI) ablation and those who underwent lobectomy (both p > 0.05). This cohort study suggests that T1 and T2 PTC patients with more than five positive LNM have no additional survival benefit of TT over lobectomy. If RAI ablation is not planned, lobectomy may be an effective alternative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.